Loomis, Sayles & Company
PBYI icon

Loomis, Sayles & Company’s Puma Biotechnology PBYI Stock Holding History

Loomis, Sayles & Company’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-62,796
Closed -$14.8M – 932
2015
Q1 		$14.8M Sell
62,796
-5,136
-8% -$1.1M 0.04% 412
2014
Q4 		$12.9M Sell
67,932
-19,755
-23% -$4.38M 0.04% 465
2014
Q3 		$20.9M Buy
+87,687
New +$18M 0.06% 295
2014
Q1 		– Sell
-24,233
Closed -$2.51M – 767
2013
Q4 		$2.51M Sell
24,233
-8,114
-25% -$476K 0.01% 593
2013
Q3 		$1.74M Buy
32,347
+2,731
+9% +$147K 0.01% 592
2013
Q2 		$1.31M Buy
+29,616
New +$1.04M ﹤0.01% 588

Other funds holding PBYI

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Grantham, Mayo, Van Otterloo & Co (GMO)
Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $44.4B AUM 36.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Loomis, Sayles & Company's PBYI Position: Q2 2015 in Review

Loomis, Sayles & Company sold out of Puma Biotechnology (PBYI) in Q2 2015, closing a stake of 62,796 shares — an estimated $14.8M sold.

Loomis, Sayles & Company first reported a position in PBYI in Q2 2013 and held it in 6 quarters. The position peaked at $20.9M in Q3 2014. 198 funds tracked by Wall St. Rank hold PBYI as of Q2 2015.

  • Loomis, Sayles & Company reported no remaining Puma Biotechnology position as of Q2 2015 after selling out during the quarter.
  • Loomis, Sayles & Company sold 62,796 Puma Biotechnology shares in Q2 2015, an estimated $14.8M.
  • Loomis, Sayles & Company first reported a position in Puma Biotechnology in Q2 2013 and held it in 6 quarters.
  • Loomis, Sayles & Company's Puma Biotechnology position peaked at $20.9M in Q3 2014.
  • 198 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2015.

Based on Loomis, Sayles & Company's 13F filing for Q2 2015, filed 14 Aug 2015.